Downregulation of SIGIRR releases IL1 signaling in tumor cells, which subsequently stimulates factors involved in activating inflammatory pathways, including the autocrine growth factor IL6, the unconventional co-transcription factor NFKBIZ, and the immune checkpoint inhibitor PD-L1 (Fig. 2D) [81]. Here, CD274 is linked to neoplasm.